Schott Pharma AG KGaA (CHIX:1SXPD) Debt-to-EBITDA : 0.00 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Schott Pharma AG KGaA Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Schott Pharma AG KGaA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.0 Mil. Schott Pharma AG KGaA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.0 Mil. Schott Pharma AG KGaA's annualized EBITDA for the quarter that ended in Dec. 2024 was €237.0 Mil. Schott Pharma AG KGaA's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Schott Pharma AG KGaA's Debt-to-EBITDA or its related term are showing as below:

CHIX:1SXPd' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.02 Med: 0.3 Max: 0.35
Current: 0.35

During the past 5 years, the highest Debt-to-EBITDA Ratio of Schott Pharma AG KGaA was 0.35. The lowest was 0.02. And the median was 0.30.

CHIX:1SXPd's Debt-to-EBITDA is ranked better than
74.72% of 443 companies
in the Medical Devices & Instruments industry
Industry Median: 1.47 vs CHIX:1SXPd: 0.35

Schott Pharma AG KGaA Debt-to-EBITDA Historical Data

The historical data trend for Schott Pharma AG KGaA's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Schott Pharma AG KGaA Debt-to-EBITDA Chart

Schott Pharma AG KGaA Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

Sep24

Debt-to-EBITDA

0.04

0.02

0.35

0.30

0.33

Schott Pharma AG KGaA Quarterly Data
	Sep20	Sep21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-EBITDA	Get a 7-Day Free Trial							-	0.39	-	0.31	-

Competitive Comparison of Schott Pharma AG KGaA's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Schott Pharma AG KGaA's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Schott Pharma AG KGaA's Debt-to-EBITDA falls into.

Save Embed

;

Save Embed

;

Schott Pharma AG KGaA Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Schott Pharma AG KGaA's Debt-to-EBITDA for the fiscal year that ended in Sep. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(4.928	+	80.874)	/	262.436
	=	0.33

Schott Pharma AG KGaA's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0)	/	236.988
	=	0.00

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.

Schott Pharma AG KGaA (CHIX:1SXPd) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Schott Pharma AG KGaA Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Schott Pharma AG KGaA's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Schott Pharma AG KGaA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Schott Pharma AG & CO KGaA (CHIX:1SXPd) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

SHTPY:USA 1SXP:Germany 1SXP:Austria

Address

Hattenbergstrasse 10, Mainz, RP, DEU, 55122

Website

https://www.schott-pharma.com

Schott Pharma AG & CO KGaA caters to the pharma, biotech and life science industry by providing containment solutions and delivery systems for injectable drugs. Its segments include; Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of the revenue is generated from Drug Containment Solutions segment which includes products like vials, cartridges and ampoules for safe drug containment. Geographically, the company generates revenue from Europe, Middle East, Africa (EMEA), Asia and South Pacific, North America and South America.

Schott Pharma AG KGaA Headlines

No Headlines